Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Tumor Necrosis Factor Inhibitors Drug Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Cimzia (Certolizumab Pegol)
      • 1.3.3 Enbrel (Etanercept)
      • 1.3.4 Humira ( Adalimumab)
      • 1.3.5 Otezla (Apremilast)
      • 1.3.6 Remicade (Infliximab)
      • 1.3.7 Simponi (Golimumab)
    • 1.4 Market Segment by Application
      • 1.4.1 Global Tumor Necrosis Factor Inhibitors Drug Market Share by Application (2019-2025)
      • 1.4.2 Clinic
      • 1.4.3 Hospital
      • 1.4.4 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size
      • 2.1.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue 2014-2025
      • 2.1.2 Global Tumor Necrosis Factor Inhibitors Drug Sales 2014-2025
    • 2.2 Tumor Necrosis Factor Inhibitors Drug Growth Rate by Regions
      • 2.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Regions 2014-2019
      • 2.2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Tumor Necrosis Factor Inhibitors Drug Sales by Manufacturers
      • 3.1.1 Tumor Necrosis Factor Inhibitors Drug Sales by Manufacturers 2014-2019
      • 3.1.2 Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Tumor Necrosis Factor Inhibitors Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Tumor Necrosis Factor Inhibitors Drug Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Tumor Necrosis Factor Inhibitors Drug Market Concentration Ratio (CR5 and HHI)
    • 3.3 Tumor Necrosis Factor Inhibitors Drug Price by Manufacturers
    • 3.4 Key Manufacturers Tumor Necrosis Factor Inhibitors Drug Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Tumor Necrosis Factor Inhibitors Drug Market
    • 3.6 Key Manufacturers Tumor Necrosis Factor Inhibitors Drug Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Cimzia (Certolizumab Pegol) Sales and Revenue (2014-2019)
      • 4.1.2 Enbrel (Etanercept) Sales and Revenue (2014-2019)
      • 4.1.3 Humira ( Adalimumab) Sales and Revenue (2014-2019)
      • 4.1.4 Otezla (Apremilast) Sales and Revenue (2014-2019)
      • 4.1.5 Remicade (Infliximab) Sales and Revenue (2014-2019)
      • 4.1.6 Simponi (Golimumab) Sales and Revenue (2014-2019)
    • 4.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type
    • 4.3 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type
    • 4.4 Tumor Necrosis Factor Inhibitors Drug Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Tumor Necrosis Factor Inhibitors Drug Sales by Application

    6 United States

    • 6.1 United States Tumor Necrosis Factor Inhibitors Drug Breakdown Data by Company
    • 6.2 United States Tumor Necrosis Factor Inhibitors Drug Breakdown Data by Type
    • 6.3 United States Tumor Necrosis Factor Inhibitors Drug Breakdown Data by Application

    7 European Union

    • 7.1 European Union Tumor Necrosis Factor Inhibitors Drug Breakdown Data by Company
    • 7.2 European Union Tumor Necrosis Factor Inhibitors Drug Breakdown Data by Type
    • 7.3 European Union Tumor Necrosis Factor Inhibitors Drug Breakdown Data by Application

    8 China

    • 8.1 China Tumor Necrosis Factor Inhibitors Drug Breakdown Data by Company
    • 8.2 China Tumor Necrosis Factor Inhibitors Drug Breakdown Data by Type
    • 8.3 China Tumor Necrosis Factor Inhibitors Drug Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Tumor Necrosis Factor Inhibitors Drug Breakdown Data by Company
    • 9.2 Rest of World Tumor Necrosis Factor Inhibitors Drug Breakdown Data by Type
    • 9.3 Rest of World Tumor Necrosis Factor Inhibitors Drug Breakdown Data by Application
    • 9.4 Rest of World Tumor Necrosis Factor Inhibitors Drug Breakdown Data by Countries
      • 9.4.1 Rest of World Tumor Necrosis Factor Inhibitors Drug Sales by Countries
      • 9.4.2 Rest of World Tumor Necrosis Factor Inhibitors Drug Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Apogenix
      • 10.1.1 Apogenix Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Inhibitors Drug
      • 10.1.4 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 10.1.5 Apogenix Recent Development
    • 10.2 AryoGen Biopharma
      • 10.2.1 AryoGen Biopharma Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Inhibitors Drug
      • 10.2.4 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 10.2.5 AryoGen Biopharma Recent Development
    • 10.3 Bionovis
      • 10.3.1 Bionovis Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Inhibitors Drug
      • 10.3.4 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 10.3.5 Bionovis Recent Development
    • 10.4 CASI Pharmaceuticals
      • 10.4.1 CASI Pharmaceuticals Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Inhibitors Drug
      • 10.4.4 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 10.4.5 CASI Pharmaceuticals Recent Development
    • 10.5 Celltrion
      • 10.5.1 Celltrion Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Inhibitors Drug
      • 10.5.4 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 10.5.5 Celltrion Recent Development
    • 10.6 Celgene Corporation
      • 10.6.1 Celgene Corporation Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Inhibitors Drug
      • 10.6.4 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 10.6.5 Celgene Corporation Recent Development
    • 10.7 Delenex Therapeutics
      • 10.7.1 Delenex Therapeutics Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Inhibitors Drug
      • 10.7.4 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 10.7.5 Delenex Therapeutics Recent Development
    • 10.8 Dexa Medica
      • 10.8.1 Dexa Medica Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Inhibitors Drug
      • 10.8.4 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 10.8.5 Dexa Medica Recent Development
    • 10.9 EPIRUS Biopharmaceuticals
      • 10.9.1 EPIRUS Biopharmaceuticals Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Inhibitors Drug
      • 10.9.4 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 10.9.5 EPIRUS Biopharmaceuticals Recent Development
    • 10.10 Janssen Biotech
      • 10.10.1 Janssen Biotech Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Tumor Necrosis Factor Inhibitors Drug
      • 10.10.4 Tumor Necrosis Factor Inhibitors Drug Product Introduction
      • 10.10.5 Janssen Biotech Recent Development
    • 10.11 GlaxoSmithKline
    • 10.12 HanAll Biopharma
    • 10.13 Intas Pharmaceuticals
    • 10.14 LEO Pharma
    • 10.15 LG Life Sciences
    • 10.16 MedImmune
    • 10.17 Momenta Pharmaceuticals
    • 10.18 Novartis
    • 10.19 PROBIOMED
    • 10.20 Reliance Life Sciences
    • 10.21 Sandoz
    • 10.22 Samsung Bioepis
    • 10.23 Sanofi-Aventis
    • 10.24 Shanghai CP Guojian Pharmaceutical
    • 10.25 Shanghai Pharmaceuticals
    • 10.26 Simcere Pharmaceutical
    • 10.27 Toyama Chemical
    • 10.28 Tsumura
    • 10.29 UCB
    • 10.30 Zydus Cadila

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Tumor Necrosis Factor Inhibitors Drug Sales Channels
      • 11.2.2 Tumor Necrosis Factor Inhibitors Drug Distributors
    • 11.3 Tumor Necrosis Factor Inhibitors Drug Customers

    12 Market Forecast

    • 12.1 Global Tumor Necrosis Factor Inhibitors Drug Sales and Revenue Forecast 2019-2025
    • 12.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Type
    • 12.3 Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Application
    • 12.4 Tumor Necrosis Factor Inhibitors Drug Forecast by Regions
      • 12.4.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Tumor Necrosis Factor Inhibitors Drug is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Tumor Necrosis Factor Inhibitors Drug.

      This report studies the global market size of Tumor Necrosis Factor Inhibitors Drug, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Tumor Necrosis Factor Inhibitors Drug sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Apogenix
      AryoGen Biopharma
      Bionovis
      CASI Pharmaceuticals
      Celltrion
      Celgene Corporation
      Delenex Therapeutics
      Dexa Medica
      EPIRUS Biopharmaceuticals
      Janssen Biotech
      GlaxoSmithKline
      HanAll Biopharma
      Intas Pharmaceuticals
      LEO Pharma
      LG Life Sciences
      MedImmune
      Momenta Pharmaceuticals
      Novartis
      PROBIOMED
      Reliance Life Sciences
      Sandoz
      Samsung Bioepis
      Sanofi-Aventis
      Shanghai CP Guojian Pharmaceutical
      Shanghai Pharmaceuticals
      Simcere Pharmaceutical
      Toyama Chemical
      Tsumura
      UCB
      Zydus Cadila

      Market Segment by Product Type
      Cimzia (Certolizumab Pegol)
      Enbrel (Etanercept)
      Humira ( Adalimumab)
      Otezla (Apremilast)
      Remicade (Infliximab)
      Simponi (Golimumab)

      Market Segment by Application
      Clinic
      Hospital
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Tumor Necrosis Factor Inhibitors Drug status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Tumor Necrosis Factor Inhibitors Drug manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Tumor Necrosis Factor Inhibitors Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now